Phase 3 Prostate Cancer Trial, Recruiting NCT07293585 Sponsor: Jonsson Comprehensive Cancer Center Condition: Prostate Cancer
Back to Prostate Cancer

Phase 3 Prostate Cancer Trial, Recruiting

NCT07293585
Recruiting Phase 3

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • People who are 18 years of age or older
  • People who have been diagnosed with prostate cancer (a specific type called adenocarcinoma) that has been confirmed by a tissue sample and has not spread beyond the prostate area
  • People who have had the recommended scans and tests to assess how far their cancer has spread, based on their risk level (advanced imaging scans may be used instead of a bone scan in some cases)
  • People who show no signs of cancer spread to lymph nodes in the upper abdomen, bones, or internal organs (some lymph node involvement lower in the pelvis may still be acceptable)
  • People who are reasonably active and able to carry out daily activities, as measured by a standard medical scale (ECOG score of 2 or lower)
  • People who are able to have a special type of MRI scan of the pelvis called a magnetic resonance angiography (MRA)
  • People who do not need urgent or emergency radiation treatment
  • People who are able to give written consent and are willing and able to follow the study requirements

Who may not be able to join:

  • People whose prostate cancer is a rare type called neuroendocrine or small cell carcinoma
  • People whose cancer has spread to distant parts of the body (some lymph node involvement in the lower pelvis area may be considered acceptable at the investigator's discretion)
  • People whose biopsy, MRI, or special PET scan shows a tumour in the middle section of the prostate or across both outer sides of the prostate
  • People who have previously had whole-prostate treatments such as cryosurgery (freezing), high-intensity focused ultrasound (HIFU), brachytherapy (internal radiation seeds), or other whole-gland ablation treatments
  • People who have previously had radiation therapy to the pelvic area
  • People with a history of Crohn's disease, ulcerative colitis, or a condition called ataxia telangiectasia
  • People who already have a penile implant or prosthesis in place before treatment begins

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 22 July 2026
Phase 3: approximately ~65% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.
Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.

Contact this trial

Principal Investigator: Amar Kishan, MD, UCLA / Jonsson Comprehensive Cancer Center

Phone: 310-267-8988

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Phase 3
Sponsor
Jonsson Comprehensive Cancer Center
Registry
ClinicalTrials.gov
Start date
16 December 2025
Est. completion
16 December 2035

Where this trial is recruiting

🇺🇸 United States

Primary endpoints

Expanded Prostate Cancer Index Composite (EPIC-26) sexual function Questionnaire

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 22 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov